HRP20100588T1 - O-supstituirani derivati dibenzil-uree kao antagonisti trpv1 receptora - Google Patents
O-supstituirani derivati dibenzil-uree kao antagonisti trpv1 receptora Download PDFInfo
- Publication number
- HRP20100588T1 HRP20100588T1 HR20100588T HRP20100588T HRP20100588T1 HR P20100588 T1 HRP20100588 T1 HR P20100588T1 HR 20100588 T HR20100588 T HR 20100588T HR P20100588 T HRP20100588 T HR P20100588T HR P20100588 T1 HRP20100588 T1 HR P20100588T1
- Authority
- HR
- Croatia
- Prior art keywords
- trifluoromethyl
- benzyl
- urea
- methoxybenzyl
- alkyl
- Prior art date
Links
- 108010025083 TRPV1 receptor Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- -1 2,3-dihydroxypropyl Chemical group 0.000 claims abstract 21
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract 8
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract 6
- 150000002367 halogens Chemical group 0.000 claims abstract 6
- 239000001257 hydrogen Substances 0.000 claims abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract 5
- 229910052794 bromium Inorganic materials 0.000 claims abstract 5
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 5
- 239000000460 chlorine Substances 0.000 claims abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims abstract 3
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims abstract 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000003277 amino group Chemical group 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract 2
- 239000011630 iodine Substances 0.000 claims abstract 2
- 229910052740 iodine Inorganic materials 0.000 claims abstract 2
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 2
- 230000003287 optical effect Effects 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- RJKLLYDQVZVXKC-UHFFFAOYSA-N 1-[(4-tert-butylphenyl)methyl]-3-[[2-chloro-4-(2-hydroxyethoxy)-5-methoxyphenyl]methyl]urea Chemical compound C1=C(OCCO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1Cl RJKLLYDQVZVXKC-UHFFFAOYSA-N 0.000 claims 1
- PUZWTTSBDBYVPS-OAQYLSRUSA-N 1-[[2-(4-chlorophenyl)-4-[(2r)-2,3-dihydroxypropoxy]-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=1C=C(Cl)C=CC=1C=1C=C(OC[C@H](O)CO)C(OC)=CC=1CNC(=O)NCC1=CC=C(C(F)(F)F)C=C1 PUZWTTSBDBYVPS-OAQYLSRUSA-N 0.000 claims 1
- GGTHQBFHHFVEAR-UHFFFAOYSA-N 1-[[2-bromo-4-(2,3-dihydroxypropoxy)-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(OCC(O)CO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=C1Br GGTHQBFHHFVEAR-UHFFFAOYSA-N 0.000 claims 1
- BGZNIBURMVYLKH-UHFFFAOYSA-N 1-[[2-bromo-4-(2-hydroxyethoxy)-5-methoxyphenyl]methyl]-3-[(4-tert-butylphenyl)methyl]urea Chemical compound C1=C(OCCO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(C)(C)C)=C1Br BGZNIBURMVYLKH-UHFFFAOYSA-N 0.000 claims 1
- VCHBJYOKHZTYIS-UHFFFAOYSA-N 1-[[2-bromo-4-(2-hydroxyethoxy)-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(OCCO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=C1Br VCHBJYOKHZTYIS-UHFFFAOYSA-N 0.000 claims 1
- GGTHQBFHHFVEAR-OAHLLOKOSA-N 1-[[2-bromo-4-[(2r)-2,3-dihydroxypropoxy]-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(OC[C@H](O)CO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=C1Br GGTHQBFHHFVEAR-OAHLLOKOSA-N 0.000 claims 1
- HYMWCTATPXZGQO-UHFFFAOYSA-N 1-[[2-chloro-4-(2,3-dihydroxypropoxy)-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(OCC(O)CO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=C1Cl HYMWCTATPXZGQO-UHFFFAOYSA-N 0.000 claims 1
- FXFSXQYVXCLVIA-UHFFFAOYSA-N 1-[[2-chloro-4-(2-hydroxyethoxy)-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(OCCO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=C1Cl FXFSXQYVXCLVIA-UHFFFAOYSA-N 0.000 claims 1
- HYMWCTATPXZGQO-OAHLLOKOSA-N 1-[[2-chloro-4-[(2r)-2,3-dihydroxypropoxy]-5-methoxyphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C1=C(OC[C@H](O)CO)C(OC)=CC(CNC(=O)NCC=2C=CC(=CC=2)C(F)(F)F)=C1Cl HYMWCTATPXZGQO-OAHLLOKOSA-N 0.000 claims 1
- LHPPGMMDLSIVLX-OAQYLSRUSA-N 1-[[4-[(2r)-2,3-dihydroxypropoxy]-5-methoxy-2-phenylphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=1C=CC=CC=1C=1C=C(OC[C@H](O)CO)C(OC)=CC=1CNC(=O)NCC1=CC=C(C(F)(F)F)C=C1 LHPPGMMDLSIVLX-OAQYLSRUSA-N 0.000 claims 1
- JHYIFYRYVUNNJF-HXUWFJFHSA-N 1-[[4-[(2r)-2,3-dihydroxypropoxy]-5-methoxy-2-pyridin-3-ylphenyl]methyl]-3-[[4-(trifluoromethyl)phenyl]methyl]urea Chemical compound C=1C=CN=CC=1C=1C=C(OC[C@H](O)CO)C(OC)=CC=1CNC(=O)NCC1=CC=C(C(F)(F)F)C=C1 JHYIFYRYVUNNJF-HXUWFJFHSA-N 0.000 claims 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 208000014617 hemorrhoid Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/06—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms
- C07C335/10—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C335/12—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Spojevi formule (I) naznačeni time da jeR odabran od sljedećih: halogen, alkil, alkoksi, aril te heteroaril; R1 odabran od sljedećih: 2-hidroksietil, 2,3-dihidroksipropil, 3-hidroksipropil, 2,2-dihidroksietil, 3,3-dihidroksipropil, 1,3-dioksolan-etil, 1,3-dioksan-metil, 1,3-dioksolan-metil, 1,3-dioksan-etil, 3-fluor-2-hidroksipropil, 3-karboksi-2-hidroksi-propil, 3-klor-2-hidroksipropil, 2-hidroksipropil, 2-hidroksi-propen-2-il, morfolinoetil, piperazinoetil, hidroksimetil, benzil, 4-(hidroksimetil)benzil, 4-klorbenzil, 4-fluorbenzil, te 4-hidroksibenzilR2 tert-butil ili trifluormetil; R3 neovinso odabran od sljedećih: vodik, karboksi, cijano, alkil ili hidroksialkil, uključujući sve njihove moguće optičke izomere i dijastereomere, pri čemu "halogen" jest atom halogena odabran od sljedećih: fluor, klor, brom te jod; "alkil" jest ravna ili razgranata (C1-C4)alkilna skupina; "alkoksi" jest ravna ili razgranata (C1-C4)alkoksilna skupina; "aril" jest fenil, koji može biti supstituiran s jednim ili više od sljedećih: halogen, alkilna te alkoksilne skupina kako su ovdje prije definirane, cijano ili amino skupina, koje mogu biti iste ili različite; te"heteroaril" jest petero- ili šesteročlani heterociklil koji sadrži jedan ili više atoma dušika, kisika ili sumpora, a koji mogu biti isti ili se mogu razlikovati jedan od drugog. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Spojevi formule (I)
[image]
naznačeni time da je
R odabran od sljedećih: halogen, alkil, alkoksi, aril te heteroaril;
R1 odabran od sljedećih: 2-hidroksietil, 2,3-dihidroksipropil, 3-hidroksipropil, 2,2-dihidroksietil, 3,3-dihidroksipropil, 1,3-dioksolan-etil, 1,3-dioksan-metil, 1,3-dioksolan-metil, 1,3-dioksan-etil, 3-fluor-2-hidroksipropil, 3-karboksi-2-hidroksi-propil, 3-klor-2-hidroksipropil, 2-hidroksipropil, 2-hidroksi-propen-2-il, morfolinoetil, piperazinoetil, hidroksimetil, benzil, 4-(hidroksimetil)benzil, 4-klorbenzil, 4-fluorbenzil, te 4-hidroksibenzil
R2 tert-butil ili trifluormetil;
R3 neovinso odabran od sljedećih: vodik, karboksi, cijano, alkil ili hidroksialkil, uključujući sve njihove moguće optičke izomere i dijastereomere, pri čemu
"halogen" jest atom halogena odabran od sljedećih: fluor, klor, brom te jod;
"alkil" jest ravna ili razgranata (C1-C4)alkilna skupina;
"alkoksi" jest ravna ili razgranata (C1-C4)alkoksilna skupina;
"aril" jest fenil, koji može biti supstituiran s jednim ili više od sljedećih: halogen, alkilna te alkoksilne skupina kako su ovdje prije definirane, cijano ili amino skupina, koje mogu biti iste ili različite; te
"heteroaril" jest petero- ili šesteročlani heterociklil koji sadrži jedan ili više atoma dušika, kisika ili sumpora, a koji mogu biti isti ili se mogu razlikovati jedan od drugog.
2. Spojevi prema patentnom zahtjevu 1, naznačeni time da:
R jest klor ili brom;
R1 jest 2-hidroksietil;
R2 jest tert-butil ili trifluormetil;
R3 jest vodik.
3. Spojevi prema patentnom zahtjevu 1, naznačeni time da:
R jest klor ili brom;
R1 jest 2-2,3-dihidroksipropil;
R2 jest trifluormetil;
R3 jest vodik.
4. Spojevi prema patentnom zahtjevu 1, naznačeni time da:
R jest metil, fenil, piridin ili 4-(supstituirani)-fenil;
R1 jest (R)-(-)-2,3-dihidroksipropil;
R2 jest trifluormetil;
R3 jest vodik.
5. Spojevi prema patentnom zahtjevu 1, naznačeni time da:
R jest klor ili brom;
R1 jest (R)-(-)-2,3-dihidroksipropil;
R2 jest trifluormetil;
R3 jest vodik.
6. Spoj prema patetntnom zahtjevu 1, naznačen time da je odabran od sljedećih:
1-[4-(2-hidroksietoksi)-2-brom-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-(2-hidroksietoksi)-2-klor-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-(2-hidroksietoksi)-2-brom-5-metoksibenzil]-3-[4-(tert-butil)-benzil]-urea;
1-[4-(2-hidroksietoksi)-2-klor-5-metoksibenzil]-3-[4-(tert-butil)-benzil]-urea;
1-[4-(2,3-dihidroksipropoksi)-2-klor-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-(2,3-dihidroksipropoksi)-2-brom-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-((R)-(-)-2,3-dihidroksipropoksi)-2-klor-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-((R)-(-)-2,3-dihidroksipropoksi)-2-fenil-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-((R)-(-)-2,3-dihidroksipropoksi)-2-(piridin-3-il)-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-((R)-(-)-2,3-dihidroksipropoksi)-2-(4-klorfenil)-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea;
1-[4-((R)-(-)-2,3-dihidroksipropoksi)-2-brom-5-metoksibenzil]-3-[4-(trifluormetil)-benzil]-urea.
7. Spojevi formule (I) kako su definirani u bilo kojem od patentnih zahtjeva 1 do 6, naznačeni time da su za upotrebu kao lijekovi.
8. Upotreba spojeva formule (I) kako su definirani u bilo kojem od patentnih zahtjeva 1 do 6, naznačena time da je za preparaciju farmaeutskih pripravaka za terapiju upalnih stanja.
9. Upotreba prema patentnom zahtjevu 8, naznačena time da je upalno stanje odabrano od sljedećih: kronična neuropatksa bolest, sindrom hiperaktivnog mjehura, bolest uzrokovana tumorom, hemeroidi, upalna hiperalgezija, bol nakon intervencije, vađenje zuba, upala dišnih puteva te gastro-intestinalna bolest.
10. Farmaceutski pripravak koji sadrži spojeve formule (I) kako su definirani u bilo kojem od patentnih zahtjeva 1 do 6, naznačen time da je u smjesi s pogodnim ekscipijensima i/ili vezikulima.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06026533A EP1939173A1 (en) | 2006-12-21 | 2006-12-21 | O-substituted-dibenzyl urea- or thiourea- derivatives as trpv1 receptor antagonists |
| PCT/IB2007/003784 WO2008075150A1 (en) | 2006-12-21 | 2007-12-06 | O-substituted-dibenzyl urea-derivatives as trpv1 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100588T1 true HRP20100588T1 (hr) | 2010-12-31 |
Family
ID=38139789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100588T HRP20100588T1 (hr) | 2006-12-21 | 2010-11-02 | O-supstituirani derivati dibenzil-uree kao antagonisti trpv1 receptora |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7750049B2 (hr) |
| EP (2) | EP1939173A1 (hr) |
| JP (1) | JP5302214B2 (hr) |
| KR (1) | KR101460177B1 (hr) |
| CN (1) | CN101563317B (hr) |
| AT (1) | ATE479652T1 (hr) |
| BR (1) | BRPI0720421A2 (hr) |
| CA (1) | CA2673219C (hr) |
| CY (1) | CY1110833T1 (hr) |
| DE (1) | DE602007008942D1 (hr) |
| DK (1) | DK2094653T3 (hr) |
| EA (1) | EA015152B1 (hr) |
| ES (1) | ES2347492T3 (hr) |
| HR (1) | HRP20100588T1 (hr) |
| IL (1) | IL199422A (hr) |
| MX (1) | MX2009006582A (hr) |
| NO (1) | NO20092336L (hr) |
| NZ (1) | NZ577796A (hr) |
| PL (1) | PL2094653T3 (hr) |
| PT (1) | PT2094653E (hr) |
| RS (1) | RS51555B (hr) |
| SI (1) | SI2094653T1 (hr) |
| UA (1) | UA95986C2 (hr) |
| WO (1) | WO2008075150A1 (hr) |
| ZA (1) | ZA200904278B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2203411B1 (en) | 2007-09-20 | 2016-01-06 | Ramot at Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
| EP3547991A1 (en) | 2016-12-02 | 2019-10-09 | Symrise AG | Cosmetic blends |
| RU2755206C1 (ru) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Средство пролонгированного анальгетического действия и лекарственный препарат на его основе |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8715357D0 (en) * | 1987-06-30 | 1987-08-05 | Sandoz Inst For Medical Resear | Organic compounds |
| GB9519270D0 (en) * | 1995-09-21 | 1995-11-22 | Sandoz Pharma Uk | Organic compounds |
| CN100439332C (zh) * | 2000-08-21 | 2008-12-03 | 株式会社太平洋 | 硫脲衍生物以及包含该衍生物的药物组合物 |
| JP2003192660A (ja) * | 2001-12-26 | 2003-07-09 | Bayer Ag | 尿素誘導体 |
| US6858615B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| ITMI20041231A1 (it) * | 2004-06-18 | 2004-09-18 | Pharmeste Srl | Antagonisti del recettore dei vanilloidi trpv1 |
-
2006
- 2006-12-21 EP EP06026533A patent/EP1939173A1/en not_active Withdrawn
-
2007
- 2007-06-12 UA UAA200904805A patent/UA95986C2/uk unknown
- 2007-12-06 MX MX2009006582A patent/MX2009006582A/es active IP Right Grant
- 2007-12-06 WO PCT/IB2007/003784 patent/WO2008075150A1/en active Application Filing
- 2007-12-06 CN CN2007800469258A patent/CN101563317B/zh active Active
- 2007-12-06 PL PL07848984T patent/PL2094653T3/pl unknown
- 2007-12-06 JP JP2009542247A patent/JP5302214B2/ja active Active
- 2007-12-06 DE DE602007008942T patent/DE602007008942D1/de active Active
- 2007-12-06 AT AT07848984T patent/ATE479652T1/de active
- 2007-12-06 DK DK07848984.6T patent/DK2094653T3/da active
- 2007-12-06 EP EP07848984A patent/EP2094653B1/en active Active
- 2007-12-06 EA EA200900625A patent/EA015152B1/ru not_active IP Right Cessation
- 2007-12-06 ZA ZA200904278A patent/ZA200904278B/xx unknown
- 2007-12-06 ES ES07848984T patent/ES2347492T3/es active Active
- 2007-12-06 US US12/519,753 patent/US7750049B2/en active Active
- 2007-12-06 CA CA2673219A patent/CA2673219C/en active Active
- 2007-12-06 SI SI200730412T patent/SI2094653T1/sl unknown
- 2007-12-06 PT PT07848984T patent/PT2094653E/pt unknown
- 2007-12-06 KR KR1020097012641A patent/KR101460177B1/ko active IP Right Grant
- 2007-12-06 RS RSP-2010/0441A patent/RS51555B/en unknown
- 2007-12-06 NZ NZ577796A patent/NZ577796A/en not_active IP Right Cessation
- 2007-12-06 BR BRPI0720421-3A patent/BRPI0720421A2/pt not_active IP Right Cessation
-
2009
- 2009-06-18 IL IL199422A patent/IL199422A/en active IP Right Grant
- 2009-06-18 NO NO20092336A patent/NO20092336L/no not_active Application Discontinuation
-
2010
- 2010-10-18 CY CY20101100925T patent/CY1110833T1/el unknown
- 2010-11-02 HR HR20100588T patent/HRP20100588T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602007008942D1 (de) | 2010-10-14 |
| US7750049B2 (en) | 2010-07-06 |
| CA2673219C (en) | 2015-04-14 |
| ES2347492T3 (es) | 2010-10-29 |
| IL199422A (en) | 2015-01-29 |
| PT2094653E (pt) | 2010-09-23 |
| KR101460177B1 (ko) | 2014-11-10 |
| SI2094653T1 (sl) | 2011-01-31 |
| EA200900625A1 (ru) | 2009-12-30 |
| DK2094653T3 (da) | 2010-10-25 |
| JP2010513455A (ja) | 2010-04-30 |
| WO2008075150A1 (en) | 2008-06-26 |
| ZA200904278B (en) | 2010-08-25 |
| EP1939173A1 (en) | 2008-07-02 |
| US20100105740A1 (en) | 2010-04-29 |
| CN101563317B (zh) | 2012-12-12 |
| EA015152B1 (ru) | 2011-06-30 |
| NO20092336L (no) | 2009-06-18 |
| CY1110833T1 (el) | 2015-06-10 |
| MX2009006582A (es) | 2009-07-02 |
| NZ577796A (en) | 2011-10-28 |
| EP2094653A1 (en) | 2009-09-02 |
| ATE479652T1 (de) | 2010-09-15 |
| CN101563317A (zh) | 2009-10-21 |
| CA2673219A1 (en) | 2008-06-26 |
| EP2094653B1 (en) | 2010-09-01 |
| PL2094653T3 (pl) | 2011-02-28 |
| RS51555B (en) | 2011-06-30 |
| JP5302214B2 (ja) | 2013-10-02 |
| UA95986C2 (uk) | 2011-09-26 |
| KR20090090347A (ko) | 2009-08-25 |
| BRPI0720421A2 (pt) | 2013-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170453T1 (hr) | Sinteza stirilpiridina radioaktivno obilježenih s 18f iz tosilatnih preteča i njihovi stabilni farmaceutski pripravci | |
| DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| RU2011121567A (ru) | Изоиндолиновые соединения для применения при лечении рака | |
| PE20091321A1 (es) | Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion en terapeutica | |
| JP2014502979A5 (hr) | ||
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| JP2005536475A5 (hr) | ||
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| EA201000805A1 (ru) | Бис-(сульфониламино)производные в терапии 066 | |
| DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| NO20060981L (no) | Pyridazinderivater og deres anvendelse som terapeutiske midler | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| WO2006125180B1 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| CY1116190T1 (el) | Φαρμακευτικη συνθεση η οποια περιεχει οπτικα ενεργη ενωση που διαθετει δραστικοτητα αγωνιστη υποδοχεα θρομβοποιητινης και ενδιαμεσο γι' αυτην | |
| DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2007525533A5 (hr) | ||
| PE20220964A1 (es) | Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas | |
| HRP20100588T1 (hr) | O-supstituirani derivati dibenzil-uree kao antagonisti trpv1 receptora | |
| JP2014523888A5 (hr) | ||
| RU2009146132A (ru) | Карбамоилоксиарилалканоиларилпиперазиновое соединение, фармацевтические композиции, содержащие его, и способ лечения боли, беспокойства и депрессии |